blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

Podcast recap: Melissa Haendel on building a rare disease data ecosystem from ontology to equity

In a recent episode of The Genetics Podcast, Dr. Melissa Haendel, Director of Translational Informatics and Precision Health and Professor at the University of ...
Continue reading

Podcast recap: Huma Qamar on pioneering gene therapy for retinal disease

In a recent episode of The Genetics Podcast, Dr. Huma Qamar, Chief Medical Officer at Ocugen, shares her extraordinary journey from a small town in Pakistan to ...
Continue reading

Personalized medicine for DMD: Genetics to treatment

Duchenne muscular dystrophy (DMD) is an inherited disorder that is characterized by progressive muscle degeneration, leading to loss of function and premature d...
Continue reading

How precision medicine is advancing myasthenia gravis treatment

Myasthenia gravis (MG) is a chronic neuromuscular disorder (NMD) that is characterized by muscle fatigue and weakness. It is considered a rare disease, affectin...
Continue reading

Podcast recap: Frank Gleeson on targeting muscle regeneration to tackle Duchenne muscular dystrophy

On a recent episode of The Genetics Podcast, Patrick spoke with Frank Gleeson, co-founder and CEO of Satellos Bioscience, a Canadian biotech pioneering a regene...
Continue reading

Understanding CRISPR evolution: A decade of progress, a breakthrough, and what’s next

News of a ‘CRISPR baby’ broke this week, almost seven years after the first CRISPR baby scandal unleashed a media frenzy and years of ethical debates. But this ...
Continue reading

Partnering to unlock the next chapter in lupus research

We’re proud to share that Sano Genetics plays a key role in the newly announced Lupus Nexus Foundational Analyses, a groundbreaking initiative led by the Lupus ...
Continue reading

Clinical trial recruitment for rare disease: AI + JIT

Clinical trial recruitment remains one of the most persistent bottlenecks in drug development. Across therapeutic areas, trials routinely face delays, cost over...
Continue reading

Modernizing rare disease trials with patient-centered innovation

While there have been significant strides in the development of drugs for rare diseases over the past few decades, only 5% of rare diseases have FDA-approved tr...
Continue reading

Podcast recap: Kent Rogers on building a path for N-of-1 therapies and transforming rare disease treatment

In a recent episode of The Genetics Podcast, Patrick spoke with Kent Rogers, CEO of EveryONE Medicines, about the future of individualized medicines, especially...
Continue reading